Biotech firm IRBM, whose lab is based south of Rome, is cooperating with AstraZeneca in developing a vaccine for the disease which has caused more than 35,600 deaths in Italy. “It is possible to have the first shots in Italy by the end of November, provided the trial continues as planned and the vaccine is validated,” Matteo Liguori said on Wednesday. Italy’s Health Minister had already said the vaccine could be available by the end of 2020. (Reporting by Emilio Parodi; Writing by Angelo Amante; Editing by Alexander Smith) Please note you must be a Maverick Insider to comment. Sign up here or sign in if you are already an Insider. Everybody has an opinion but not everyone has the knowledge and the experience to contribute meaningfully to a discussion. That’s what we want from our members. Help us learn with your expertise and insights on articles that we publish. We encourage different, respectful viewpoints to further our understanding of the world. View our comments policy here. No Comments, yet